SCHEMBL1132587

SCHEMBL1132587

O=C(O)c1ccccc1-c1cccc2c1C=Nc1ccccc1N2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 2/20 0.40
FOLH1 Q04609 2/20 0.40
MYC P01106 1/20 0.39
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
ALOX12 P18054 1/20 0.38
ALOX5 P09917 1/20 0.38
LIG1 P18858 1/20 0.37
RAB9A P51151 2/20 0.37
KDM4E B2RXH2 2/20 0.37
HNF4A P41235 1/20 0.36
ALDH1A1 P00352 4/20 0.36
GAA P10253 1/20 0.36
MEN1 O00255 1/20 0.36
USP2 O75604 1/20 0.36
PPARG P37231 1/20 0.36
KMT2A Q03164 1/20 0.36
KEAP1 Q14145 1/20 0.36
NFE2L2 Q16236 1/20 0.36
HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1132588 0.72 LMNA (0.49) FOLH1MYCCYP3A4CYP2C9ALOX12
SCHEMBL27478110 0.71 TRPA1 (0.49) TRPA1CYP3A4KDM4EALDH1A1HSD17B10
SCHEMBL1773148 0.69 MEN1 (0.40) KDM4EALDH1A1GAAMEN1USP2
SCHEMBL2552199 0.69 MEN1 (0.40) KDM4EALDH1A1GAAMEN1USP2
SCHEMBL36145 0.69 ALDH1A1 (0.72) FOLH1MYCCYP3A4CYP2C9ALOX12
SCHEMBL30028907 0.69 ALDH1A1 (0.72) FOLH1MYCCYP3A4CYP2C9ALOX12
Hydrochloric Acid SCHEMBL1681943 0.67 ALDH1A1 (0.68) FOLH1MYCCYP3A4CYP2C9ALOX12
SCHEMBL2830888 0.67 ALDH1A1 (0.68) FOLH1MYCCYP3A4CYP2C9ALOX12
Hydrochloric Acid SCHEMBL10888462 0.67 ALDH1A1 (0.68) FOLH1MYCCYP3A4CYP2C9ALOX12
Hydrochloric Acid SCHEMBL7579852 0.67 ALDH1A1 (0.68) FOLH1MYCCYP3A4CYP2C9ALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8431613-B2 Memory fixation accelerator RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2013-04-30 US disclosed
US-20120214763-A1 MEMORY FIXATION ACCELERATOR KEMPHYS LTD. (JP) 2012-08-23 US disclosed
US-8198329-B2 Memory consolidation promoting agent and method of use RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2012-06-12 US disclosed
US-8168677-B2 Method for treatment of inflammatory bowel disease KEMPHYS LTD. (JP) 2012-05-01 US disclosed
US-7902260-B2 Using a retinoid such as 4-((5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalenyl)carbamoyl)benzoic acid KEMPHYS LTD. (JP) 2011-03-08 US disclosed
EP-2286807-A2 Medicament for preventive and/or therapeutic treatment of adhesion of bowel Kemphys Ltd. (JP) 2011-02-23 EP disclosed
US-20100324134-A1 MEDICAMENT FOR PREVENTIVE AND/OR THERAPEUTIC TREATMENT OF BOWEL DISEASE KEMPHYS LTD. (JP) 2010-12-23 US disclosed
US-20100004203-A1 MEDICAMENT FOR PREVENTIVE AND/OR THERAPEUTIC TREATMENT OF BOWEL DISEASE KEMPHYS LTD. (JP) 2010-01-07 US disclosed
EP-2127645-A1 PHARMACEUTICAL AGENT FOR PREVENTION AND/OR TREATMENT OF LOWER URINARY TRACT SYMPTOM Kemphys Ltd. (JP) 2009-12-02 EP disclosed
US-20090281184-A1 PHARMACEUTICAL FOR PREVENTION AND TREATMENT OF OPHTHALMIC DISEASE INDUCED BY IN-CREASE IN VASOPERMEABILITY SAPPORO MEDICAL UNIVERSITY (JP) 2009-11-12 US disclosed
US-20080255069-A1 Medicament for Preventive and/or Therapeutic Treatment of Bowel Disease R & R INC. (JP) 2008-10-16 US disclosed
US-20080207768-A1 MEDICAMENT FOR PREVENTIVE AND/OR THERAPEUTIC TREATMENT OF LOWER URINARY TRACT SYMPTOM R&R INC. (JP) 2008-08-28 US disclosed
EP-1938815-A1 PHARMACEUTICAL FOR PREVENTION AND TREATMENT OF OPHTHALMIC DISEASE INDUCED BY INCREASE IN VASOPERMEABILITY Sapporo Medical University (JP) 2008-07-02 EP disclosed
US-20080139842-A1 Medicament for preventive and/or therapeutic treatment of diseases with secretory disorder R&R INC. (JP) 2008-06-12 US disclosed
EP-1930001-A1 PHARMACEUTICAL FOR USE IN PREVENTION AND/OR TREATMENT OF BOWEL DISEASE R & R Inc. (JP) 2008-06-11 EP disclosed
US-20080021108-A1 Memory Fixation Accelerator RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2008-01-24 US disclosed
EP-1733722-A1 MEMORY FIXATION ACCELERATOR Research Foundation Itsuu Laboratory (JP) 2006-12-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207768-A1 MEDICAMENT FOR PREVENTIVE AND/OR THERAPEUTIC TREATMENT OF LOWER URINARY TRACT SYMPTOM RARG, RARB, RARA TRPA1 2383/4885FOLH1 28/4885MYC 4345/4885
US-20080255069-A1 Medicament for Preventive and/or Therapeutic Treatment of Bowel Disease FABP2, RARG, RARA TRPA1 3083/4885FOLH1 434/4885MYC 3180/4885
US-20120214763-A1 MEMORY FIXATION ACCELERATOR BDNF, RXRA, RARA TRPA1 4015/4885FOLH1 1995/4885MYC 3490/4885
US-20100324134-A1 MEDICAMENT FOR PREVENTIVE AND/OR THERAPEUTIC TREATMENT OF BOWEL DISEASE FABP2, RARG, RARA TRPA1 3083/4885FOLH1 434/4885MYC 3180/4885
US-20080021108-A1 Memory Fixation Accelerator BDNF, RARA, RXRA TRPA1 4077/4885FOLH1 1934/4885MYC 3529/4885
US-20080139842-A1 Medicament for preventive and/or therapeutic treatment of diseases with secretory disorder RARA, RBP1, RARG TRPA1 3447/4885FOLH1 2924/4885MYC 4464/4885
US-20100004203-A1 MEDICAMENT FOR PREVENTIVE AND/OR THERAPEUTIC TREATMENT OF BOWEL DISEASE FABP2, RARG, RARA TRPA1 3083/4885FOLH1 434/4885MYC 3180/4885
US-20090281184-A1 PHARMACEUTICAL FOR PREVENTION AND TREATMENT OF OPHTHALMIC DISEASE INDUCED BY IN-CREASE IN VASOPERMEABILITY RBP4, RBP1, ALDH1A2 TRPA1 1870/4885FOLH1 529/4885MYC 2998/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.